Snakes, Jellyfish and Spiders

  • Bart J. Currie
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 609)

Our knowledge of animal and human physiological processes owes much to over a century of study of natural toxins. The neurotoxins of kraits (bungarotoxins from Bungarus spp.) and cobras (Naja spp.) have helped define the acetylcholine receptor and neuromuscular transmission. Axonal trafficking and sodium channels have been studied using tetrodotoxin from the blue-ringed octopus (Hapalochlaena spp.) and puffer fish (fugu). Unravelling the complexities of the human coagulation pathways (intrinsic and extrinsic) has involved studies using haemotoxins from various snakes, including Russell's vipers (Daboia russelii), the saw-scaled vipers (Echis spp.) and the Australian taipans (Oxyuranus spp.). Ancrod is a snake venom enzyme from the Malayan pit viper (Calloselasma rhodostoma) which has been successfully used to treat thrombotic stroke.


Ecthyma Gangrenosum Cutaneous Anthrax Toxicol Clin Toxicol Brown Recluse Spider Spider Bite 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Burnett JW, Hepper KP, Aurelian L, Calton GJ, and Gardepe SF. (1987). Recurrent eruptions following unusual solitary coelenterate envenomations. J Am Acad Dermatol, 17:86–92.PubMedCrossRefGoogle Scholar
  2. Cheng AC and Currie BJ. (2004). Venomous snakebites worldwide with a focus on the Australia-Pacific region: current management and controversies. J Intensive Care Med, 19:259–269.PubMedCrossRefGoogle Scholar
  3. Chippaux JP. (1998). Snake-bites: appraisal of the global situation. Bull World Health Organ, 76:515–524.PubMedGoogle Scholar
  4. Corkeron M, Pereira P, and Makrocanis C. (2004). Early experience with magnesium administration in Irukandji syndrome. Anaesth Intensive Care, 32:666–669.PubMedGoogle Scholar
  5. Currie BJ. (2003). Marine antivenoms. J Toxicol Clin Toxicol, 41:301–308.PubMedCrossRefGoogle Scholar
  6. Currie BJ. (2004). Snakebite in tropical Australia: a prospective study in the “Top End” of the Northern Territory. Med J Aust, 181:693–697.PubMedGoogle Scholar
  7. Currie BJ and Jacups SP. (2005). Prospective study of Chironex fleckeri and other box jellyfish stings in the “Top End” of Australia’s Northern Territory. Med J Aust, 183:631–636.PubMedGoogle Scholar
  8. Dominguez TJ. (2004). It’s not a spider bite, it’s community-acquired methicillin-resistant Staphylococcus aureus. J Am Board Fam Pract, 17:220–226.PubMedCrossRefGoogle Scholar
  9. Endean R. (1988). Venom of Chironex, the world’s most venomous animal. In Pearn J and Covacevich J (eds.), Venoms and Victims. Queensland Museum, Brisbane, pp. 15–24.Google Scholar
  10. Endean R and Sizemore DJ. (1988). The effectiveness of antivenom in countering the actions of box-jellyfish (Chironex fleckeri) nematocyst toxins in mice. Toxicon, 26:425–431.PubMedCrossRefGoogle Scholar
  11. Fenner PJ and Hadok JC. (2002). Fatal envenomation by jellyfish causing Irukandji syndrome. Med J Aust, 177:362–363.PubMedGoogle Scholar
  12. Gutierrez JM, Rojas E, Quesada L, Leon G, Nunez J, Laing GD, Sasa M, Renjifo JM, Nasidi A, Warrell DA, Theakston RD, and Rojas G. (2005). Pan-African polyspecific antivenom produced by caprylic acid purification of horse IgG: an alternative to the antivenom crisis in Africa. Trans R Soc Trop Med Hyg, 99:468–475.PubMedCrossRefGoogle Scholar
  13. Gutierrez JM, Theakston RD, and Warrell DA. (2006). Confronting the neglected problem of snake bite envenoming: the need for a global partnership. PLoS Med, 3:e150.PubMedCrossRefGoogle Scholar
  14. Huynh TT, Seymour J, Pereira P, Mulcahy R, Cullen P, Carrette T, and Little M. (2003). Severity of Irukandji syndrome and nematocyst identification from skin scrapings. Med J Aust, 178:38–41.PubMedGoogle Scholar
  15. Isbister GK. (2004). Necrotic arachnidism: the mythology of a modern plague. Lancet, 364:549–553.PubMedCrossRefGoogle Scholar
  16. Isbister GK and Gray MR. (2002). A prospective study of 750 definite spider bites, with expert spider identification. QJM, 95:723–731.PubMedCrossRefGoogle Scholar
  17. Isbister GK and Gray MR. (2003). White-tail spider bite: a prospective study of 130 definite bites by Lampona species. Med J Aust, 179:199–202.PubMedGoogle Scholar
  18. Isbister GK and White J. (2004). Clinical consequences of spider bites: recent advances in our understanding. Toxicon, 43:477–492.PubMedCrossRefGoogle Scholar
  19. Isbister GK, Graudins A, White J, and Warrell D. (2003). Antivenom treatment in arachnidism. J Toxicol Clin Toxicol, 41:291–300.PubMedCrossRefGoogle Scholar
  20. Isbister GK, Gray MR, Balit CR, Raven RJ, Stokes BJ, Porges K, Tankel AS, Turner E, White J, and Fisher MM. (2005). Funnel-web spider bite: a systematic review of recorded clinical cases. Med J Aust, 182:407–411.PubMedGoogle Scholar
  21. Kavanau JL. (2006). Is sleep’s ‘supreme mystery’ unraveling? An evolutionary analysis of sleep encounters no mystery; nor does life’s earliest sleep, recently discovered in jellyfish. Med Hypotheses, 66:3–9.PubMedCrossRefGoogle Scholar
  22. Laing GD, Renjifo JM, Ruiz F, Harrison RA, Nasidi A, Gutierrez JM, Rowley PD, Warrell DA, and Theakston RD. (2003). A new Pan African polyspecific antivenom developed in response to the antivenom crisis in Africa. Toxicon, 42:35–41.PubMedCrossRefGoogle Scholar
  23. Laing GD, Yarleque A, Marcelo A, Rodriguez E, Warrell DA, and Theakston RD. (2004). Preclinical testing of three South American antivenoms against the venoms of five medically-important Peruvian snake venoms. Toxicon, 44:103–106.PubMedCrossRefGoogle Scholar
  24. Lalloo DG and Theakston RD. (2003). Snake antivenoms. J Toxicol Clin Toxicol, 41:277–90; 317–327.PubMedCrossRefGoogle Scholar
  25. Little M, Pereira P, Carrette T, and Seymour J. (2006). Jellyfish responsible for Irukandji syndrome. QJM, 99:425–427.PubMedCrossRefGoogle Scholar
  26. McCann CM, Bracamontes J, Steinbach JH, and Sanes JR. (2006). The cholinergic antagonist alpha-bungarotoxin also binds and blocks a subset of GABA receptors. Proc Natl Acad Sci U S A, 103:5149–5154.PubMedCrossRefGoogle Scholar
  27. Nuchter T, Benoit M, Engel U, Ozbek S, and Holstein TW. (2006). Nanosecond-scale kinetics of nematocyst discharge. Curr Biol, 16:R316–R318.PubMedCrossRefGoogle Scholar
  28. O’Reilly GM, Isbister GK, Lawrie PM, Treston GT, and Currie BJ. (2001). Prospective study of jellyfish stings from tropical Australia, including the major box jellyfish Chironex fleckeri. Med J Aust, 175:652–655.PubMedGoogle Scholar
  29. Pardal PP, Souza SM, Monteiro MR, Fan HW, Cardoso JL, Franca FO, Tomy SC, Sano-Martins IS, de Sousa-e-Silva MC, Colombini M, Kodera NF, Moura-da-Silva AM, Cardoso DF, Velarde DT, Kamiguti AS, Theakston RD, and Warrell DA. (2004). Clinical trial of two antivenoms for the treatment of Bothrops and Lachesis bites in the north eastern Amazon region of Brazil. Trans R Soc Trop Med Hyg, 98:28–42.PubMedCrossRefGoogle Scholar
  30. Rocha e Silva M, Beraldo WT, and Rosenfeld G. (1949). Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am J Physiol, 156:261–273.PubMedGoogle Scholar
  31. Sekine-Aizawa Y and Huganir RL. (2004). Imaging of receptor trafficking by using alpha-bungarotoxin-binding-site-tagged receptors. Proc Natl Acad Sci U S A, 101:17114–17119.PubMedCrossRefGoogle Scholar
  32. Seymour JE, Carrette TJ, and Sutherland PA. (2004). Do box jellyfish sleep at night? Med J Aust, 181:707.PubMedGoogle Scholar
  33. Smalligan R, Cole J, Brito N, Laing GD, Mertz BL, Manock S, Maudlin J, Quist B, Holland G, Nelson S, Lalloo DG, Rivadeneira G, Barragan ME, Dolley D, Eddleston M, Warrell DA, and Theakston RD. (2004). Crotaline snake bite in the Ecuadorian Amazon: randomised double blind comparative trial of three South American polyspecific antivenoms. BMJ, 329:1129.PubMedCrossRefGoogle Scholar
  34. Swanson DL and Vetter RS. (2005). Bites of brown recluse spiders and suspected necrotic arachnidism. N Engl J Med 352:700–707.PubMedCrossRefGoogle Scholar
  35. Vetter RS, Isbister GK, Bush SP, and Boutin LJ. (2006). Verified bites by yellow sac spiders (Genus Cheiracanthium) in the United States and Australia: where is the necrosis? Am J Trop Med Hyg, 74:1043–1048.PubMedGoogle Scholar
  36. Warrell DA. (2005). Treatment of bites by adders and exotic venomous snakes. BMJ, 331:1244–1247.PubMedCrossRefGoogle Scholar
  37. White J. (2003). Debunking spider bite myths. Med J Aust, 179:180–181.PubMedGoogle Scholar
  38. Williamson JA, Fenner PJ, Burnett JW, and Rifkin JF. (1996). Venomous and Poisonous Marine Animals–A Medical and Biological Handbook. University of New South Wales Press, Sydney.Google Scholar
  39. Winkel KD, Tibballs J, Molenaar P, Lambert G, Coles P, Ross-Smith M, Wiltshire C, Fenner PJ, Gershwin LA, Hawdon GM, Wright CE, and Angus JA. (2005). Cardiovascular actions of the venom from the Irukandji (Carukia barnesi) jellyfish: effects in human, rat and guinea-pig tissues in vitro and in pigs in vitro. Clin Exp Pharmacol Physiol, 32:777–788.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Bart J. Currie
    • 1
  1. 1.Tropical and Emerging Infectious Diseases Division, Menzies School of Health ResearchCharles Darwin University, Northern Territory Clinical School, Flinders University, Royal Darwin HospitalCasuarinaAustralia

Personalised recommendations